Remimazolam anaphylaxis during anesthesia induction

Area of Science:

• Anesthesiology
• Clinical Immunology
• Pharmacology

Background:

• Anaphylaxis during anesthesia is a critical emergency requiring prompt recognition and management.
• Remimazolam is a short-acting benzodiazepine used for general anesthesia induction.
• Previous exposure to structurally similar drugs, like midazolam, can lead to sensitization.

Observation:

• A 32-year-old male developed anaphylaxis during remimazolam infusion for general anesthesia.
• Symptoms included facial flushing, decreased oxygen saturation, and hypotension shortly after remimazolam administration.
• Intradermal allergy testing 4 weeks postoperatively revealed positive reactions to both remimazolam and midazolam.

Findings:

• Remimazolam was identified as the likely causative agent for anaphylaxis in this patient.
• The patient's prior exposure to midazolam may have induced sensitization, leading to cross-reactivity with remimazolam.
• Serum tryptase levels did not increase, underscoring the importance of clinical presentation and allergy testing.

Implications:

• This case suggests remimazolam can cause anaphylaxis, necessitating vigilance during its use.
• Potential cross-reactivity between remimazolam and midazolam should be considered in patients with prior benzodiazepine exposure.
• Further research into the immunogenicity and allergic potential of remimazolam is warranted to ensure patient safety in anesthesia.